368 related articles for article (PubMed ID: 21817114)
1. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
2. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
[TBL] [Abstract][Full Text] [Related]
3. Icariin sensitizes human colon cancer cells to TRAIL‑induced apoptosis via ERK‑mediated upregulation of death receptors.
Kim B; Seo JH; Lee KY; Park B
Int J Oncol; 2020 Mar; 56(3):821-834. PubMed ID: 32124960
[TBL] [Abstract][Full Text] [Related]
4. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
[TBL] [Abstract][Full Text] [Related]
5. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
[TBL] [Abstract][Full Text] [Related]
6. Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin.
Hwang JS; Lee HC; Oh SC; Lee DH; Kwon KH
Tumour Biol; 2015 Nov; 36(11):8819-29. PubMed ID: 26063410
[TBL] [Abstract][Full Text] [Related]
7. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
8. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.
Gupta SC; Reuter S; Phromnoi K; Park B; Hema PS; Nair M; Aggarwal BB
J Biol Chem; 2011 Jan; 286(2):1134-46. PubMed ID: 21078664
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
[TBL] [Abstract][Full Text] [Related]
12. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
Na YJ; Lee DH; Kim JL; Kim BR; Park SH; Jo MJ; Jeong S; Kim HJ; Lee SY; Jeong YA; Oh SC
Int J Biochem Cell Biol; 2017 Aug; 89():147-156. PubMed ID: 28624529
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
14. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
15. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5.
Lee YS; Lee DH; Jeong SY; Park SH; Oh SC; Park YS; Yu J; Choudry HA; Bartlett DL; Lee YJ
J Cell Biochem; 2019 Jan; 120(1):928-939. PubMed ID: 30160785
[TBL] [Abstract][Full Text] [Related]
17. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
[TBL] [Abstract][Full Text] [Related]
18. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
19. Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.
Raviv Z; Zilberberg A; Cohen S; Reischer-Pelech D; Horrix C; Berger MR; Rosin-Arbesfeld R; Flescher E
Br J Pharmacol; 2011 Nov; 164(5):1433-44. PubMed ID: 21486277
[TBL] [Abstract][Full Text] [Related]
20. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]